Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID–19 patients: a single–center retrospective cohort study
Administering additional doses of TCZ beyond the initial dose was not associated with further reductions in mortality or improvements in other major clinical outcomes in patients with severe or critical COVID-19.
Authors
- Xian Peng (ORCID: https://orcid.org/0000-0001-8479-5944)
- Shuxiang Zhang (ORCID: https://orcid.org/0000-0001-7629-9895)
- Jie Cheng
- Yu Ding (ORCID: https://orcid.org/0000-0002-3688-7294)
- Jing Wang (ORCID: https://orcid.org/0000-0003-3185-1724)
- Wenjing Zhang (ORCID: https://orcid.org/0000-0001-6263-5384)
- Jie Gao
- Jing Gao (ORCID: https://orcid.org/0000-0003-4265-8276)
- Yuting Li (ORCID: https://orcid.org/0000-0002-5185-137X)
- Wei Zhou (ORCID: https://orcid.org/0000-0001-7534-3065)
Institutions
- Ningxia Hui Autonomous Region Peoples Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.3389/fphar.2025.1571372
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00